Compare ONDS & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONDS | TERN |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.8B |
| IPO Year | 2015 | 2021 |
| Metric | ONDS | TERN |
|---|---|---|
| Price | $10.20 | $52.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $19.83 | ★ $45.22 |
| AVG Volume (30 Days) | ★ 57.2M | 3.2M |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.04 |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $50,731,000.00 | N/A |
| Revenue This Year | $662.14 | N/A |
| Revenue Next Year | $76.37 | N/A |
| P/E Ratio | $17.49 | ★ N/A |
| Revenue Growth | ★ 605.31 | N/A |
| 52 Week Low | $1.00 | $3.02 |
| 52 Week High | $15.28 | $53.19 |
| Indicator | ONDS | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 55.62 | 74.51 |
| Support Level | $8.16 | $52.42 |
| Resistance Level | $11.87 | $53.19 |
| Average True Range (ATR) | 0.84 | 0.07 |
| MACD | 0.05 | -0.31 |
| Stochastic Oscillator | 52.88 | 97.30 |
Ondas Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system. Geographically, the company operates in Israel, Germany, United Arab Emirates, United States, and Other Countries. It derives maximum revenue from Israel.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.